Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association

Valeria Visconte, Arda Durmaz, Hussein Awada, Ishani Nautiyal, Tariq Kewan, Waled Bahaj, Anjali Advani, Caroline Astbury, Heesun J. Rogers, Jaroslaw P. Maciejewski, Carmelo Gurnari

Blood (2022) 140 (Supplement 1): 6886–6887.

https://doi.org/10.1182/blood-2022-167770

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

ANKRD26 Coding Variants in Myeloid Neoplasia

Teodora Kuzmanovic, Metis Hasipek, Samuel Li, Thomas Laframboise, Valeria Visconte, Sunisa Kongkiatkamon, Seth J. Corey, Sudipto Mukherjee, Anjali Advani, Aaron T. Gerds, Yogenthiran Saunthararajah, Sophia R. Balderman, Abhay Singh Singh, Hetty E. Carraway, Niroshan Nadarajah, Manja Meggendorfer, Jaroslaw P. Maciejewski, Bhumika J. Patel

Blood (2022) 140 (Supplement 1): 4013–4015.

https://doi.org/10.1182/blood-2022-170645

Published: 2022

Journal Articles

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Julia H. Joo, Yanwen Chen, Aaron T. Gerds, Anjali Advani, Sophia R. Balderman, Hetty E. Carraway, Abhay Singh Singh, Sudipto Mukherjee

Blood (2022) 140 (Supplement 1): 687–689.

https://doi.org/10.1182/blood-2022-163565

Published: 2022

Journal Articles

Genomic Landscape of PHD Finger Protein 6 ( PHF6 ) Mutant Myeloid Neoplasia

Laila Terkawi, Carmelo Gurnari, Sunisa Kongkiatkamon, Simona Pagliuca, Minako Mori, Hassan Awada, Ishani Pandit, Christopher Haddad, Tariq Kewan, Waled Bahaj, Misam Zawit, Babal K. Jha, Hetty E. Carraway, Anjali Advani, Jaroslaw P. Maciejewski, Valeria Visconte

Blood (2021) 138 (Supplement 1): 1154.

https://doi.org/10.1182/blood-2021-153554

Published: 2021

Journal Articles

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Lori Muffly, Jun Yin, Sawyer Jacobson, Anjali Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Frederick R. Appelbaum, Richard A. Larson, Theresa Keegan, Wendy Stock

Blood (2021) 138 (Supplement 1): 337.

https://doi.org/10.1182/blood-2021-148804

Published: 2021

Journal Articles

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 372.

https://doi.org/10.1182/blood-2021-146503

Published: 2021

Journal Articles

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba

Blood (2021) 138 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2021-145529

Published: 2021

Journal Articles

Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML

Tariq Kewan, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Hassan Awada, Suresh Kumar Balasubramanian, Bhumika J. Patel, Sudipto Mukherjee, Anjali Advani, Valeria Visconte, Hetty E. Carraway, James R. Cook, Heesun J. Rogers, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2021-151803

Published: 2021

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2021-146585

Published: 2021

Journal Articles

Germline and Somatic Variants of CSF3R Define Distinct Myeloid Neoplasia Syndromes

Tariq Kewan, Hrishikesh M Mehta, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Suresh Kumar Balasubramanian, Bhumika J. Patel, Anjali Advani, Valeria Visconte, Hetty E. Carraway, Seth J. Corey, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 3667.

https://doi.org/10.1182/blood-2021-152546

Published: 2021

Journal Articles

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

Tariq Kewan, Ramsha Ahmed, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Yogenthiran Saunthararajah, Bhumika J. Patel, Sudipto Mukherjee, Aaron T. Gerds, Anjali Advani, Valeria Visconte, Jaroslaw P. Maciejewski, Hetty E. Carraway

Blood (2021) 138 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2021-151858

Published: 2021

Journal Articles

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Abby Statler, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A. Sekeres

Blood (2018) 131 (25): 2782–2788.

https://doi.org/10.1182/blood-2018-01-826693

Published: 2018

Includes: Supplemental data

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD

Blood (2016) 128 (22): 211.

https://doi.org/10.1182/blood.V128.22.211.211

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD

Blood (2016) 128 (22): 340.

https://doi.org/10.1182/blood.V128.22.340.340

Published: 2016

Journal Articles

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Ronan LE Moigne, PhD, Valeria Visconte, PhD, Bartlomiej Przychodzen, MSc, Mark Rolfe, PhD, Stevan Djakovic, PhD, Daniel Anderson, David Wustrow, PhD, Han-Jie Zhou, Steve Wong, PhD, Anjali Advani, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2015) 126 (23): 1350.

https://doi.org/10.1182/blood.V126.23.1350.1350

Published: 2015

Journal Articles

Long-Term Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia

Moaath Mustafa Ali, MD, Donna M Abounader, Lisa A. Rybicki, MS, Jamie Starn, RN, BSN, Christina Ferraro, RN, BSN, Victoria Winslow, RN, BSN, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Hien Liu, MD, Robert M. Dean, MD, Rabi Hanna, MD, Matt Kalaycio, MD, Brian J. Bolwell, MD, Anjali Advani, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2015) 126 (23): 5534.

https://doi.org/10.1182/blood.V126.23.5534.5534

Published: 2015

Journal Articles

Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD, MS, Alan F. List, MD, H. Jean Khoury, MD, Anjali Advani, MD, Elias Jabbour, MD, Hagop M Kantarjian, MD, Jeffrey E Lancet, MD, LouAnn Cable, MS, Kari Guthrie, Grant Hogeland, PhD, Mieke Ptaszynski, MD, Lara Maloney, BA, Donald Corson, Rami S. Komrokji, MD

Blood (2013) 122 (21): 387.

https://doi.org/10.1182/blood.V122.21.387.387

Published: 2013

NARROW

Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

ANKRD26 Coding Variants in Myeloid Neoplasia

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Genomic Landscape of PHD Finger Protein 6 ( PHF6 ) Mutant Myeloid Neoplasia

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Germline and Somatic Variants of CSF3R Define Distinct Myeloid Neoplasia Syndromes

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML

Long-Term Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia

Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only